FR2727689A1 - Nouveau procede de preparation d'un vecteur viral - Google Patents
Nouveau procede de preparation d'un vecteur viral Download PDFInfo
- Publication number
- FR2727689A1 FR2727689A1 FR9414470A FR9414470A FR2727689A1 FR 2727689 A1 FR2727689 A1 FR 2727689A1 FR 9414470 A FR9414470 A FR 9414470A FR 9414470 A FR9414470 A FR 9414470A FR 2727689 A1 FR2727689 A1 FR 2727689A1
- Authority
- FR
- France
- Prior art keywords
- vector
- dna
- sequence
- recombinant
- genome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 62
- 239000013603 viral vector Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims description 9
- 230000008569 process Effects 0.000 title description 6
- 230000003612 virological effect Effects 0.000 claims abstract description 41
- 239000013598 vector Substances 0.000 claims abstract description 36
- 239000002245 particle Substances 0.000 claims abstract description 26
- 208000015181 infectious disease Diseases 0.000 claims abstract description 21
- 230000002458 infectious effect Effects 0.000 claims abstract description 20
- 241000282414 Homo sapiens Species 0.000 claims abstract description 12
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 9
- 238000001415 gene therapy Methods 0.000 claims abstract description 7
- 238000002744 homologous recombination Methods 0.000 claims abstract description 5
- 230000006801 homologous recombination Effects 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 108020004414 DNA Proteins 0.000 claims description 59
- 239000012634 fragment Substances 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 45
- 241000700605 Viruses Species 0.000 claims description 28
- 241000701161 unidentified adenovirus Species 0.000 claims description 24
- 108091029865 Exogenous DNA Proteins 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 16
- 238000005215 recombination Methods 0.000 claims description 15
- 230000006798 recombination Effects 0.000 claims description 14
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 11
- 230000001413 cellular effect Effects 0.000 claims description 8
- 238000010367 cloning Methods 0.000 claims description 8
- 230000010076 replication Effects 0.000 claims description 8
- 230000002950 deficient Effects 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 7
- 101150047856 Cav2 gene Proteins 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 241001529453 unidentified herpesvirus Species 0.000 claims description 5
- 241000282465 Canis Species 0.000 claims description 4
- 241001430294 unidentified retrovirus Species 0.000 claims description 4
- 241000271566 Aves Species 0.000 claims description 3
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 claims description 3
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims description 3
- 108010069091 Dystrophin Proteins 0.000 claims description 3
- 102000001039 Dystrophin Human genes 0.000 claims description 3
- 241001529936 Murinae Species 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
- 239000013600 plasmid vector Substances 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
- 241000283690 Bos taurus Species 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000862 Ion Channels Proteins 0.000 claims description 2
- 102000004310 Ion Channels Human genes 0.000 claims description 2
- 108010074338 Lymphokines Proteins 0.000 claims description 2
- 102000008072 Lymphokines Human genes 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000003114 blood coagulation factor Substances 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 65
- 241001135569 Human adenovirus 5 Species 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 230000000692 anti-sense effect Effects 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 8
- 238000010276 construction Methods 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 241000714474 Rous sarcoma virus Species 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 241000598171 Human adenovirus sp. Species 0.000 description 5
- 108020005544 Antisense RNA Proteins 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 101710124413 Portal protein Proteins 0.000 description 4
- 101710083205 SAR-endolysin Proteins 0.000 description 4
- 101710092804 Tail tube protein gp19 Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000701157 Canine mastadenovirus A Species 0.000 description 3
- 239000003155 DNA primer Substances 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 101150069452 z gene Proteins 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 108010052875 Adenine deaminase Proteins 0.000 description 2
- 102100038909 Caveolin-2 Human genes 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 239000002753 trypsin inhibitor Substances 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 101150104494 CAV1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000701114 Canine adenovirus 2 Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000856267 Homo sapiens Glycerate kinase Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- -1 Phospho Chemical class 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010027570 Xanthine phosphoribosyltransferase Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 101150106093 gpt gene Proteins 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 101150111388 pac gene Proteins 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 101150047627 pgk gene Proteins 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Priority Applications (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9414470A FR2727689A1 (fr) | 1994-12-01 | 1994-12-01 | Nouveau procede de preparation d'un vecteur viral |
| EP95941755A EP0742834B9 (fr) | 1994-12-01 | 1995-12-01 | Procede de preparation d'un vecteur viral d'au moins 20kb par recombinaison homologue intermoleculaire dans une cellule procaryote |
| ES95941755T ES2150595T5 (es) | 1994-12-01 | 1995-12-01 | Procedimiento de preparacion de un vector viral de por lo menos 20 kb por recombinacion homologa intermolecular en una celula procariota. |
| DE69518910T DE69518910T3 (de) | 1994-12-01 | 1995-12-01 | Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle |
| US08/682,794 US6110735A (en) | 1994-12-01 | 1995-12-01 | Method for the preparation of a viral vector by intermolecular homologous recombination |
| AU43068/96A AU707208B2 (en) | 1994-12-01 | 1995-12-01 | Method for the preparation of a viral vector by intermolecular homologous recombination |
| DK95941755T DK0742834T4 (da) | 1994-12-01 | 1995-12-01 | Fremgangsmåde til fremstilling af en virusvektor på mindst 20 kb ved intermolekylær homolog rekombination i en prokaryot celle |
| JP51834696A JP3989541B2 (ja) | 1994-12-01 | 1995-12-01 | 分子間相同組換えによるウイルスベクターの作製方法 |
| DE69518910A DE69518910D1 (de) | 1994-12-01 | 1995-12-01 | Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle |
| AT95941755T ATE196507T1 (de) | 1994-12-01 | 1995-12-01 | Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle |
| CA002182303A CA2182303C (fr) | 1994-12-01 | 1995-12-01 | Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire |
| PT95941755T PT742834E (pt) | 1994-12-01 | 1995-12-01 | Processo de preparacao de um vector viral de, pelo menos 20 kb por recombinacao homologa intermolecular numa celula procariota |
| PCT/FR1995/001590 WO1996017070A1 (fr) | 1994-12-01 | 1995-12-01 | Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire |
| US09/467,952 US6281000B1 (en) | 1994-12-01 | 1999-12-21 | Method for the preparation of a viral vector by intermolecular homologous recombination |
| GR20000402737T GR3035050T3 (en) | 1994-12-01 | 2000-12-12 | Method of preparing a viral vector by homologous intermolecular recombination |
| US09/938,491 US7067310B2 (en) | 1994-12-01 | 2001-08-27 | Method for the preparation of a viral vector by inter-molecular homologous recombination |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9414470A FR2727689A1 (fr) | 1994-12-01 | 1994-12-01 | Nouveau procede de preparation d'un vecteur viral |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2727689A1 true FR2727689A1 (fr) | 1996-06-07 |
| FR2727689B1 FR2727689B1 (enExample) | 1997-02-28 |
Family
ID=9469390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9414470A Granted FR2727689A1 (fr) | 1994-12-01 | 1994-12-01 | Nouveau procede de preparation d'un vecteur viral |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US6110735A (enExample) |
| EP (1) | EP0742834B9 (enExample) |
| JP (1) | JP3989541B2 (enExample) |
| AT (1) | ATE196507T1 (enExample) |
| AU (1) | AU707208B2 (enExample) |
| CA (1) | CA2182303C (enExample) |
| DE (2) | DE69518910T3 (enExample) |
| DK (1) | DK0742834T4 (enExample) |
| ES (1) | ES2150595T5 (enExample) |
| FR (1) | FR2727689A1 (enExample) |
| GR (1) | GR3035050T3 (enExample) |
| PT (1) | PT742834E (enExample) |
| WO (1) | WO1996017070A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6569677B1 (en) | 1997-04-02 | 2003-05-27 | Transgene S.A. | Modified adenoviral fiber and target adenoviruses |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2727689A1 (fr) * | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| FR2730504B1 (fr) * | 1995-02-13 | 1997-03-28 | Rhone Poulenc Rorer Sa | Procede de preparation de genomes d'adenovirus recombinants |
| US6720140B1 (en) * | 1995-06-07 | 2004-04-13 | Invitrogen Corporation | Recombinational cloning using engineered recombination sites |
| US6143557A (en) * | 1995-06-07 | 2000-11-07 | Life Technologies, Inc. | Recombination cloning using engineered recombination sites |
| AU8067698A (en) * | 1997-06-09 | 1998-12-30 | Genvec, Inc. | Chimeric vectors comprising a phage packaging site and a portion derived from a genome of a eukaryotic virus |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| WO1999015686A1 (en) | 1997-09-23 | 1999-04-01 | Genvec, Inc. | Plasmids for construction of eukaryotic viral vectors |
| CN101125873A (zh) * | 1997-10-24 | 2008-02-20 | 茵维特罗根公司 | 利用具重组位点的核酸进行重组克隆 |
| DE69836092T2 (de) * | 1997-10-24 | 2007-05-10 | Invitrogen Corp., Carlsbad | Rekombinatorisches klonieren unter verwendung von nukleinsaüren mit rekombinationsstellen |
| US5922576A (en) * | 1998-02-27 | 1999-07-13 | The John Hopkins University | Simplified system for generating recombinant adenoviruses |
| US6670188B1 (en) * | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| US7691370B2 (en) * | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
| DE60042969D1 (de) * | 1999-03-02 | 2009-10-29 | Life Technologies Corp | Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren |
| EP1248851A2 (en) * | 1999-12-07 | 2002-10-16 | Genethon III | Canine adenovirus vectors for the transfer of genes in targeted cells |
| ATE391789T1 (de) * | 1999-12-10 | 2008-04-15 | Invitrogen Corp | Verwendung einer vielzahl von rekombinationsstellen mit einzigartiger spezifität beim rekombinatorischen klonen |
| ES2394877T3 (es) * | 2000-08-14 | 2013-02-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Recombinación homóloga mejorada mediada por proteínas de recombinación de lambda |
| US7198924B2 (en) * | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
| GB0027501D0 (en) * | 2000-11-10 | 2000-12-27 | Astrazeneca Ab | Vector |
| JP2004513638A (ja) * | 2000-11-10 | 2004-05-13 | アストラゼネカ・アクチエボラーグ | ベクター |
| US8071314B2 (en) * | 2001-12-14 | 2011-12-06 | President And Fellows Of Harvard College | Immunocellular receptors related to neurological disorders and therapeutic uses thereof |
| US7521242B2 (en) * | 2003-05-09 | 2009-04-21 | The United States Of America As Represented By The Department Of Health And Human Services | Host cells deficient for mismatch repair and their use in methods for inducing homologous recombination using single-stranded nucleic acids |
| CN103484486B (zh) * | 2003-07-02 | 2018-04-24 | 维莱尼姆公司 | 葡聚糖酶，编码它们的核酸以及制备和使用它们的方法 |
| ES2356154T3 (es) | 2003-07-21 | 2011-04-05 | Transgene S.A. | Citoquinas multifuncionales. |
| DK1649023T3 (da) | 2003-07-21 | 2008-10-06 | Transgene Sa | Polypeptid med forbedret cytosindeaminaseaktivitet |
| DE602004027538D1 (de) | 2003-12-01 | 2010-07-15 | Life Technologies Corp | Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon |
| US7674621B2 (en) | 2004-05-21 | 2010-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Plasmids and phages for homologous recombination and methods of use |
| US20060234347A1 (en) * | 2005-04-13 | 2006-10-19 | Harding Thomas C | Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| EP2468300B1 (en) | 2006-09-26 | 2017-12-20 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| CL2008000249A1 (es) | 2007-01-30 | 2008-05-30 | Transgene Sa | Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| CA2744294A1 (en) | 2009-01-13 | 2010-07-22 | Transgene Sa | Use of a saccharomyces cerevisiae mitochondrial nucleic acids fraction for immune stimulation |
| PT2382474E (pt) | 2009-01-20 | 2015-06-03 | Transgene Sa | Icam-1 solúvel como biomarcador para a previsão de uma resposta terapêutica |
| BRPI1009892A2 (pt) | 2009-03-24 | 2016-03-15 | Transgène S A | método ex-vivo para avaliar a eficácia de um tratamento em um paciente, e, kit para testar se um paciente está respondendo terapeuticamente a um método de tratamento compreendendo administração de uma composição imunogênica |
| BRPI1010512A2 (pt) | 2009-04-17 | 2016-03-15 | Transgène S A | "método ex vivo para avaliar a eficácia de um tratamento envolvendo a administração de uma composição imunogênica a um paciente, e, uso de níveis de linfócitos t ativados (cd3 + cd69+) como um biomarcador" |
| CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| US20110015256A1 (en) * | 2009-07-16 | 2011-01-20 | Ihab Mamdouh Ishak Sadek | Delivery of restriction endonucleases to treat hiv, cancer, and other medical conditions |
| CA2770075C (en) | 2009-08-07 | 2021-08-24 | Perrine Martin | Composition for treating hbv infection |
| NZ616304A (en) | 2011-04-08 | 2016-01-29 | Immune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| PL2811981T3 (pl) | 2012-02-07 | 2019-09-30 | Infectious Disease Research Institute | Ulepszone formulacje adiuwantowe zawierające agonistę TLR4 oraz sposoby ich zastosowania |
| SMT201800368T1 (it) | 2012-05-16 | 2018-09-13 | Immune Design Corp | Vaccini per l'infezione da virus-2 herpes simplex |
| JP6430949B2 (ja) | 2012-10-23 | 2018-11-28 | エモリー ユニバーシティ | Ｇｍ−ｃｓｆとｉｌ−４のコンジュゲート、組成物、ならびにそれに関連する方法 |
| CA2909221A1 (en) | 2013-04-18 | 2014-10-23 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| CA2975432A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| RU2761870C2 (ru) | 2016-05-16 | 2021-12-13 | Инфекшес Дизис Рисёрч Инститьют | Состав, содержащий агонист tlr, и способы применения |
| EP3463300A1 (en) | 2016-06-01 | 2019-04-10 | Infectious Disease Research Institute | Nanoalum particles containing a sizing agent |
| MX2019003161A (es) | 2016-09-20 | 2019-05-27 | Boehringer Ingelheim Vetmedica Gmbh | Nuevo sitio de insercion orf70 de ehv. |
| UY37408A (es) | 2016-09-20 | 2018-03-23 | Boehringer Ingelheim Vetmedica Gmbh | Vacuna de vectores contra el virus de la gripe “a” porcina |
| ES2956050T3 (es) | 2016-09-20 | 2023-12-12 | Boehringer Ingelheim Vetmedica Gmbh | Vectores de adenovirus caninos |
| MX391049B (es) | 2016-09-20 | 2025-03-21 | Boehringer Ingelheim Vetmedica Gmbh | Nuevos promotores |
| WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
| CN110418650A (zh) | 2016-11-16 | 2019-11-05 | 免疫治疗有限公司 | 用于治疗过敏的核酸 |
| EP3612556B8 (en) | 2017-04-22 | 2024-11-20 | Immunomic Therapeutics, Inc. | Improved lamp constructs |
| WO2018204534A1 (en) | 2017-05-02 | 2018-11-08 | Immunomic Therapeutics, Inc. | Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens |
| EP3678695A1 (en) | 2017-09-08 | 2020-07-15 | Infectious Disease Research Institute | Liposomal formulations comprising saponin and methods of use |
| JP2021523185A (ja) | 2018-05-15 | 2021-09-02 | イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | アレルゲンを含む改善されたｌａｍｐ構築物 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| US12680122B2 (en) | 2019-10-08 | 2026-07-14 | Trustees Of Boston College | Proteins containing multiple, different unnatural amino acids and methods of making and using such proteins |
| KR20220083773A (ko) | 2019-10-18 | 2022-06-20 | 이뮤노믹 쎄라퓨틱스, 인크. | 암 항원을 포함하는 개선된 lamp 구축물 |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
| TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
| JP2023517011A (ja) | 2020-03-05 | 2023-04-21 | ネオティーエックス セラピューティクス リミテッド | 免疫細胞を用いて癌を治療するための方法および組成物 |
| WO2021209897A1 (en) | 2020-04-13 | 2021-10-21 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022009051A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
| CA3247515A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003400A1 (en) * | 1993-07-23 | 1995-02-02 | Johns Hopkins University School Of Medicine | Recombinationally targeted cloning in yeast artificial chromosomes |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| GB9001766D0 (en) * | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| FR2727689A1 (fr) * | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| US5582362A (en) * | 1995-03-31 | 1996-12-10 | Johnson; John R. | Center feed toilet paper dispenser |
-
1994
- 1994-12-01 FR FR9414470A patent/FR2727689A1/fr active Granted
-
1995
- 1995-12-01 EP EP95941755A patent/EP0742834B9/fr not_active Expired - Lifetime
- 1995-12-01 AT AT95941755T patent/ATE196507T1/de active
- 1995-12-01 DK DK95941755T patent/DK0742834T4/da active
- 1995-12-01 ES ES95941755T patent/ES2150595T5/es not_active Expired - Lifetime
- 1995-12-01 DE DE69518910T patent/DE69518910T3/de not_active Expired - Lifetime
- 1995-12-01 WO PCT/FR1995/001590 patent/WO1996017070A1/fr not_active Ceased
- 1995-12-01 AU AU43068/96A patent/AU707208B2/en not_active Expired
- 1995-12-01 JP JP51834696A patent/JP3989541B2/ja not_active Expired - Lifetime
- 1995-12-01 CA CA002182303A patent/CA2182303C/fr not_active Expired - Lifetime
- 1995-12-01 US US08/682,794 patent/US6110735A/en not_active Expired - Lifetime
- 1995-12-01 DE DE69518910A patent/DE69518910D1/de not_active Expired - Lifetime
- 1995-12-01 PT PT95941755T patent/PT742834E/pt unknown
-
1999
- 1999-12-21 US US09/467,952 patent/US6281000B1/en not_active Expired - Lifetime
-
2000
- 2000-12-12 GR GR20000402737T patent/GR3035050T3/el unknown
-
2001
- 2001-08-27 US US09/938,491 patent/US7067310B2/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003400A1 (en) * | 1993-07-23 | 1995-02-02 | Johns Hopkins University School Of Medicine | Recombinationally targeted cloning in yeast artificial chromosomes |
Non-Patent Citations (6)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6569677B1 (en) | 1997-04-02 | 2003-05-27 | Transgene S.A. | Modified adenoviral fiber and target adenoviruses |
| US7256036B2 (en) | 1997-04-02 | 2007-08-14 | Transgene | Modified adenoviral fiber and target adenoviruses |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2182303C (fr) | 2005-06-21 |
| DK0742834T3 (da) | 2001-01-29 |
| ATE196507T1 (de) | 2000-10-15 |
| DE69518910T4 (de) | 2006-02-09 |
| US6110735A (en) | 2000-08-29 |
| FR2727689B1 (enExample) | 1997-02-28 |
| EP0742834B2 (fr) | 2005-08-03 |
| DE69518910D1 (de) | 2000-10-26 |
| AU707208B2 (en) | 1999-07-08 |
| EP0742834A1 (fr) | 1996-11-20 |
| DK0742834T4 (da) | 2005-08-22 |
| CA2182303A1 (fr) | 1996-06-06 |
| WO1996017070A1 (fr) | 1996-06-06 |
| ES2150595T3 (es) | 2000-12-01 |
| US20020090715A1 (en) | 2002-07-11 |
| AU4306896A (en) | 1996-06-19 |
| PT742834E (pt) | 2001-03-30 |
| JPH09509330A (ja) | 1997-09-22 |
| EP0742834B9 (fr) | 2005-12-28 |
| ES2150595T5 (es) | 2005-12-01 |
| GR3035050T3 (en) | 2001-03-30 |
| US7067310B2 (en) | 2006-06-27 |
| DE69518910T2 (de) | 2001-03-29 |
| US6281000B1 (en) | 2001-08-28 |
| JP3989541B2 (ja) | 2007-10-10 |
| EP0742834B1 (fr) | 2000-09-20 |
| DE69518910T3 (de) | 2006-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0742834B1 (fr) | Procede de preparation d'un vecteur viral d'au moins 20kb par recombinaison homologue intermoleculaire dans une cellule procaryote | |
| EP0784693B1 (fr) | Vecteurs viraux pour la therapie genique | |
| EP0919627B1 (fr) | Nouvelles lignées cellulaires de complémentation pour vecteurs adénoviraux defectifs | |
| EP1035208B1 (en) | VARIANT LoxP SEQUENCES AND APPLICATION OF THE SAME | |
| EP0842279B1 (fr) | Virus auxiliaires pour la preparation de vecteurs viraux recombinants | |
| EP1016711B1 (fr) | Procédé d'inactivation de virus enveloppés dans une préparation virale d'adénovirus | |
| EP0809704B1 (fr) | Procede de preparation de genome d'adenovirus recombinants | |
| EP1032695B1 (fr) | Vecteurs adenoviraux et methode de reduction des evenements de recombinaison homologue | |
| WO1996025506A9 (fr) | Procede de preparation de genome d'adenovirus recombinants | |
| FR2763959A1 (fr) | Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage | |
| CA2197904A1 (fr) | Adenovirus recombinants defectifs avec un gene iva2 inactive | |
| EP0906443B1 (fr) | Generation de molecules replicatives in vivo | |
| WO1997044475A1 (fr) | Vecteurs adenoviraux pour la therapie genique | |
| EP1006123A2 (fr) | Protéines d'enveloppe, methodes et utilisations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |